RGD肽在肿瘤靶向纳米给药系统中的应用  

Research progress in RGD peptides modified tumor targeting nano drug delivery systems

作　　者：李茜[1,2] 杜永忠[2] 袁弘[2] 胡富强[2] 林陈水[1] 

机构地区：[1]浙江工业大学,杭州310014 [2]浙江大学,杭州310058

出　　处：《海峡药学》2011年第6期80-82,共3页Strait Pharmaceutical Journal

摘　　要：RGD肽是一类含有精氨酸一甘氨酸一天冬氨酸(Arg-Gly-Asp)的短肽,作为肿瘤细胞或者新生血管特异表达的整合素和其配体相互作用的识别位点,可介导肿瘤的靶向治疗。抗肿瘤药物及其递送系统经过RGD肽修饰,可增加药物的肿瘤主动靶向特性,达到更有效、精确和安全的治疗。本文主要综述了RGD肽在脂质体、聚合物胶束、基因载体等纳米给药系统中的研究应用及进展。The tripeptide arginine glycine aspartic acid（RGD） as an recognition site between integrin on the surface of tumor cell or new vessels of tumor and its ligands was wildly accepted for the tumor targeting therapy.The conjugation of RGD to antitumor agent or its drug delivery system could enhance the drug accumulation inside tumor tissue,and reached a safe and higher performance tumor therapy.This review summarized the recent development of RGD peptides in tumor targeting nano drug deliver systems,especially in liposomes,polymeric micelles and non-viral vectors.

关 键 词：RGD肽 肿瘤靶向 纳米给药系统 

分 类 号：R969.4[医药卫生—药理学]